IQVIA HOLDINGS INC. IQV

The clinical business experienced significant positive momentum in Q3 FY25, with net bookings reaching $2.6 billion, marking a 1.15x net book-to-bill ratio. This reflects improving customer demand, with bookings up 5% sequentially, 13% year-over-year, and 21% from the Q1 trough. EBP funding momentum is building, reaching $18 billion in Q3, and the qualified pipeline increased 6% year-over-year. RFP flow grew 20% year-over-year, with client decision-making timelines also improving sequentially, indicating a reduction in market uncertainty^🌐.

Technology & Analytics Solutions (TAS) performed well, showing slight sequential revenue growth despite tough year-over-year comparisons. This was driven by ongoing momentum from new drug launches and the strength of the commercial portfolio. IQVIA is also capitalizing on a developing trend of large pharma clients outsourcing commercial operations for established brands, leading to significant wins. The company is actively deploying highly specialized AI agents, with 90 in development covering 25 use cases, and is helping clients build AI-ready data infrastructures.

The real-world business continues to perform strongly, securing key wins with top pharma and biotech clients. Examples include leading post-market commitment studies for regulatory requirements, evaluating treatment outcomes in specific patient populations (e.g., African-American patients with lung cancer), and supporting regulatory commitments for rare oncology diseases. This segment's growth is attributed to IQVIA's advanced capabilities and vast information assets in real-world patient data, leveraging AI tools for evaluation.

R&D Solutions (R&DS) continued its positive momentum from Q2 into Q3. Standout wins include leading a Phase I trial for a novel leukemia treatment for a first-time sponsor, and an exclusive CRO partnership for a biotech's entire cardiovascular program. Large pharma engagements were also strong, with selections to lead a Phase II stroke therapy study and a global Phase III MASH program leveraging AI-enabled pathology tools. IQVIA is also expanding its presence in Phase I oncology work, a segment with increasing demand.

The company announced a planned CFO transition, with Mike Fedock stepping into the role on February 28, 2026, succeeding Ron Bruehlman, who will retire after a long tenure. Ron will remain as a senior advisor to ensure a smooth transition. Ron was instrumental in key company events, including the IMS Health IPO and the Quintiles merger. Mike brings deep industry experience, having served as CFO for the R&D Solutions business and IQVIA Laboratory business.

Management noted a reduction in market uncertainty^🌐 and an improved macro political environment, which has favorably impacted decision-making at large pharma. The elevated level of cancellations seen in FY24 due to large pharma program reprioritizations (e.g., IRA impact) has largely subsided, with current cancellation rates returning to normal business patterns. Pricing dynamics have also normalized, with earlier temporary discounts no longer a significant factor, leading to a healthier sector environment.